| Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms E Rumi, S Zibellini, E Boveri, C Cavalloni, R Riboni, IC Casetti, ... American journal of hematology 94 (7), E185-E188, 2019 | 32 | 2019 |
| Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib E Rumi, E Sant'Antonio, C Cavalloni, G Comolli, VV Ferretti, I Cassaniti, ... Hematological Oncology 38 (4), 554-559, 2020 | 6 | 2020 |
| Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling F Novelli, Y Yoshikawa, VAM Vitto, L Modesti, M Minaai, S Pastorino, ... Proceedings of the National Academy of Sciences 121 (29), e2405231121, 2024 | 5 | 2024 |
| The power of a novel combined anticancer therapy: Challenge and opportunity of micotherapy in the treatment of Glioblastoma Multiforme L Gaiaschi, E Roda, C Favaron, F Gola, E Gabano, M Ravera, P Rossi, ... Biomedicine & Pharmacotherapy 155, 113729, 2022 | 5 | 2022 |
| Effects of ferrocene and ferrocenium on MCF-7 breast cancer cells and interconnection with regulated cell death pathways C Favaron, E Gabano, I Zanellato, L Gaiaschi, C Casali, MG Bottone, ... Molecules 28 (18), 6469, 2023 | 4 | 2023 |
| Asbestos burden in lungs of non-occupationally exposed women from Broni (Pavia, Italy): a postmortem SEM-EDS study SD Visonà, S Capella, P Borrelli, S Villani, C Favaron, Z Kurzhunbaeva, ... Journal of Thoracic Disease 15 (12), 6555, 2023 | 2 | 2023 |
| A postmortem case control study of asbestos burden in lungs of malignant mesothelioma cases SD Visonà, B Bertoglio, C Favaron, S Capella, E Belluso, C Colosio, ... Journal of Translational Medicine 21 (1), 875, 2023 | 2 | 2023 |
| Study on the activation of cell death mechanisms: in search of new therapeutic targets in glioblastoma multiforme L Gaiaschi, C Favaron, C Casali, F Gola, F De Luca, M Ravera, E Roda, ... Apoptosis 28 (7), 1241-1257, 2023 | 2 | 2023 |
| P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN) IC Casetti, D Pietra, VV Ferretti, A De Silvestri, O Borsani, D Vanni, C Trotti, ... HemaSphere 6, 874-875, 2022 | 1 | 2022 |
| Evaluation of Asbestos Exposure SD Visonà, B Bertoglio, C Favaron, S Capella, E Belluso, C Bortolotto, ... Asbestos, 126-170, 2024 | | 2024 |
| Unraveling Novel Strategies in Mesothelioma Treatments Using a Newly Synthetized Platinum (IV) Compound C Favaron, L Gaiaschi, C Casali, F De Luca, F Gola, M Cavallo, ... Pharmaceutics 16 (8), 1015, 2024 | | 2024 |
| Cellular and molecular studies in in vitro and post-mortem models for the investigation of new targets in malignant pleural mesothelioma C Favaron Università degli studi di Pavia, 2024 | | 2024 |
| Asbestos burden in lungs of women from Broni (Pavia, Italy): a postmortem SEM-EDS study S Capella, SD Visonà, P Borrelli, S Villani, C Favaron, Z Kurzhunbaeva, ... Abstract book, 556-556, 2023 | | 2023 |
| PF669 RUXOLITINIB TREATMENT AND RISK OF B-CELL LYMPHOMAS IN MYELOPROLIFERATIVE NEOPLASMS C Cavalloni, E Rumi, S Zibellini, E Boveri, R Riboni, I Casetti, M Ciboddo, ... HemaSphere 3 (S1), 287-288, 2019 | | 2019 |
| Molecular characterization of driver and somatic subclonal variants in patients with myeloproliferative neoplasms C FAVARON | | 2017 |
